FDA Grants Orphan Drug Designation to CLR 131 in Rhabdomyosarcoma

May 15, 2018 – The U.S. Food and Drug Administration’s (FDA) Office of Orphan Products Development recently granted Orphan Drug designation to CLR 131 for the treatment of rhabdomyosarcoma, a rare pediatric cancer. “Rhabdomyosarcoma is the most common type of tissue sarcoma in children. While initial response to treatment is generally favorable, there is an important need for new treatments, especially in children who experience relapse,” said John Friend, MD, Chief … (leggi tutto)